Entera Bio Ltd. Ordinary Shares
$3.03
$0.07 (+2.36%)
$2.94Day Range$3.05
Key Statistics
Market Cap
$512.50M
Shares Outstanding
173.1M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jun 28, 2018
Round Lot
100
Locale
US
Trading Data
Day Open
$2.95
Day High
$3.05
Day Low
$2.94
Volume
310.2K
VWAP
$3.01
Prev Close
$2.96
Transactions
--
Acc. Volume
--
About Entera Bio Ltd. Ordinary Shares
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 283622 employeesKIRYAT HADASSAH, MINRAV BUILDING, JERUSALEM, 9112002972-2-532-7151IPO Jun 28, 2018US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001638097
- Ticker Root
- ENTX
- SIC Code
- 2836
About Entera Bio Ltd. Ordinary Shares (ENTX) Stock
Entera Bio Ltd. Ordinary Shares (ENTX) closed the 2026-09-17 session at $3.03, up 2.36% versus the previous close (+0.07). The stock opened at $2.95 and traded between $2.94 and $3.05 during that session. Session trading volume was 310K shares. The volume-weighted average price (VWAP) is $3.01.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
Entera Bio Ltd. Ordinary Shares has a market capitalization of $512.5 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. ENTX is listed on the XNAS exchange. The company employs approximately 22 people. The recorded listing date is 2018-06-28.
On this page you can find market ENTX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.